{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"phase I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"phase II"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Evaluate acute and chronic toxicity of the combined re-irradiation with radiosensitizing drugs: Pemetrexed and Erlotinib. Adverse events with Common Toxicity Criteria grades of 4 and 5 are reported for phase I and II.","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Evaluation of Acute and Chronic Toxicity","type":"SECONDARY","unitOfMeasure":"events"}